Collectively, these findings indicate that genetic ablation of LINC01134 not only attenuates HCC proliferation in vitro, but also substantially suppresses tumorigenesis in vivo, further supporting its classification as an oncogenic driver. This evidence concerns the gene LINC01134 and hepatocellular carcinoma.